Literature DB >> 19499344

Inhibitors of the FcRn:IgG protein-protein interaction.

Susan C Low1, Adam R Mezo.   

Abstract

The neonatal Fc receptor, FcRn, is responsible for controlling the half-life of IgG antibodies. As a result, inhibitors of FcRn have been investigated as a possible way to modulate IgG half-lives. Such inhibitors could have possible applications in reducing autoantibody levels in autoimmune disease states. To date, monoclonal antibodies, engineered Fc domains, and short peptides have been reported to inhibit FcRn function and modulate IgG half-lives in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19499344      PMCID: PMC2758113          DOI: 10.1208/s12248-009-9120-5

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  30 in total

1.  FACTORS CONTROLLING SERUM GAMMA-GLOBULIN CONCENTRATION.

Authors:  J L FAHEY; A G ROBINSON
Journal:  J Exp Med       Date:  1963-11-01       Impact factor: 14.307

2.  Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn.

Authors:  E J Israel; D F Wilsker; K C Hayes; D Schoenfeld; N E Simister
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

3.  An Fc receptor structurally related to MHC class I antigens.

Authors:  N E Simister; K E Mostov
Journal:  Nature       Date:  1989-01-12       Impact factor: 49.962

4.  The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs.

Authors:  Derry C Roopenian; Gregory J Christianson; Thomas J Sproule; Aaron C Brown; Shreeram Akilesh; Nadja Jung; Stefka Petkova; Lia Avanessian; Eun Young Choi; Daniel J Shaffer; Peter A Eden; Clark L Anderson
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

5.  Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.

Authors:  Stefka B Petkova; Shreeram Akilesh; Thomas J Sproule; Gregory J Christianson; Hana Al Khabbaz; Aaron C Brown; Leonard G Presta; Y Gloria Meng; Derry C Roopenian
Journal:  Int Immunol       Date:  2006-10-31       Impact factor: 4.823

6.  Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn.

Authors:  Adam R Mezo; Kevin A McDonnell; Cristina A Tan Hehir; Susan C Low; Vito J Palombella; James M Stattel; George D Kamphaus; Cara Fraley; Yixia Zhang; Jennifer A Dumont; Alan J Bitonti
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-12       Impact factor: 11.205

7.  Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor.

Authors:  J K Kim; M F Tsen; V Ghetie; E S Ward
Journal:  Eur J Immunol       Date:  1994-10       Impact factor: 5.532

8.  Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice.

Authors:  V Ghetie; J G Hubbard; J K Kim; M F Tsen; Y Lee; E S Ward
Journal:  Eur J Immunol       Date:  1996-03       Impact factor: 5.532

9.  Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand.

Authors:  M Raghavan; M Y Chen; L N Gastinel; P J Bjorkman
Journal:  Immunity       Date:  1994-07       Impact factor: 31.745

10.  Beta2-microglobulin-deficient mice are resistant to bullous pemphigoid.

Authors:  Z Liu; D C Roopenian; X Zhou; G J Christianson; L A Diaz; D D Sedmak; C L Anderson
Journal:  J Exp Med       Date:  1997-08-29       Impact factor: 14.307

View more
  10 in total

1.  X-ray crystal structures of monomeric and dimeric peptide inhibitors in complex with the human neonatal Fc receptor, FcRn.

Authors:  Adam R Mezo; Vandana Sridhar; John Badger; Paul Sakorafas; Vicki Nienaber
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

2.  Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice.

Authors:  Yao-Yun Fan; Lindsay B Avery; Mengmeng Wang; Denise M O'Hara; Sheldon Leung; Hendrik Neubert
Journal:  MAbs       Date:  2016-04-22       Impact factor: 5.857

3.  β2-microglobulin is required for the full expression of xenobiotic-induced systemic autoimmunity.

Authors:  Kenneth M Pollard; Per Hultman; Christopher B Toomey; David M Cauvi; Dwight H Kono; Dwight H Konoc
Journal:  J Immunotoxicol       Date:  2011 Jul-Sep       Impact factor: 3.000

4.  Identification of methionine sulfoxide diastereomers in immunoglobulin gamma antibodies using methionine sulfoxide reductase enzymes.

Authors:  Hui K Khor; Michael E Jacoby; Thomas C Squier; Grace C Chu; Dirk Chelius
Journal:  MAbs       Date:  2010-05-11       Impact factor: 5.857

Review 5.  Targeting FcRn for the modulation of antibody dynamics.

Authors:  E Sally Ward; Siva Charan Devanaboyina; Raimund J Ober
Journal:  Mol Immunol       Date:  2015-03-09       Impact factor: 4.407

Review 6.  Targeting FcRn to Generate Antibody-Based Therapeutics.

Authors:  E Sally Ward; Raimund J Ober
Journal:  Trends Pharmacol Sci       Date:  2018-08-22       Impact factor: 14.819

7.  Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.

Authors:  Peter Ulrichts; Antonio Guglietta; Torsten Dreier; Tonke van Bragt; Valérie Hanssens; Erik Hofman; Bernhardt Vankerckhoven; Peter Verheesen; Nicolas Ongenae; Valentina Lykhopiy; F Javier Enriquez; JunHaeng Cho; Raimund J Ober; E Sally Ward; Hans de Haard; Nicolas Leupin
Journal:  J Clin Invest       Date:  2018-07-24       Impact factor: 14.808

Review 8.  Rational clinical trial design for antibody mediated renal allograft injury.

Authors:  Shaifali Sandal; Martin S Zand
Journal:  Front Biosci (Landmark Ed)       Date:  2015-01-01

Review 9.  The Neonatal Fc Receptor (FcRn): A Misnomer?

Authors:  Michal Pyzik; Kine M K Sand; Jonathan J Hubbard; Jan Terje Andersen; Inger Sandlie; Richard S Blumberg
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

10.  Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers.

Authors:  Desmond Y H Yap; Jojo Hai; Paul C H Lee; Xueying Zhou; Michael Lee; Yu Zhang; Meng Wang; Xiaoxiang Chen
Journal:  Clin Transl Sci       Date:  2021-07-16       Impact factor: 4.689

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.